InBody
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
InBody makes body-composition analyzers, medical devices that measure how much muscle, fat, and water a person's body contains, along with automatic blood-pressure monitors, height-measuring instruments, and related software.
Its customers include hospitals, fitness centers, obesity clinics, military units, schools, government offices, and individual consumers. Listed on KOSDAQ, Korea's tech-focused stock exchange, InBody operates through subsidiaries across multiple continents, and the large majority of its revenue comes from markets outside Korea, with professional-grade body-composition analyzers accounting for the dominant share of total sales.
Summary is AI-generated and may contain errors · figures from DART filings
InBody is structured as a global group with domestic and overseas subsidiaries, over a dozen foreign entities spanning the Americas, Europe, and Asia-Pacific.
InBody in five facts
What does InBody do?
InBody makes body-composition analyzers, medical devices that measure how much muscle, fat, and water a person's body contains, along with automatic blood-pressure monitors, height-measuring instruments, and related software.
Where is InBody listed and in which sector?
InBody (Korean name: 인바디) trades under KRX code 041830 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Medical Devices.
How large is InBody?
Its market capitalisation was US$496.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were InBody's latest annual revenue and operating profit?
For fiscal year 2025, InBody reported revenue of US$176.6M, operating profit of US$27.7M and net income of US$22.6M, per its annual report on DART (data retrieved from DART on 2026-09-08). Revenue was up 14.4% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-08
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (abbreviated)Oct 2
- Report on securities held by executives/major shareholdersSep 30
- Report on large shareholdings (5% rule) (standard)Sep 21
- Report on securities held by executives/major shareholdersSep 21
- Report on large shareholdings (5% rule) (abbreviated)Sep 10
- Treasury share disposal: results report
InBody Co., Ltd. disposed of 1,976 treasury common shares on August 10, 2026, transferring them to its Employee Stock Ownership Association at US$40.02 per share (the closing price on the day before the August 5, 2026 board resolution) for a total of US$79.1K, leaving 132,330 treasury shares (0.98% of the 13,480,882 shares outstanding).
Treasury Shares · Aug 14 - Operating results (consolidated) (preliminary) (fair disclosure)
InBody filed provisional (unaudited) consolidated results for Q2 2026: revenue of US$51.5M (+30.4% year on year), operating profit of US$12.5M (+70.7% year on year) and net income of US$10.2M (+96.4% year on year).
Earnings · Aug 6 - [Amended] Material event report (treasury share disposal)
InBody updated a disclosed plan to sell treasury shares worth US$78.8K, about 0.0% of its market value.
Treasury Shares · Aug 6 · 2 versions - Treasury share disposal: results reportTreasury Shares · May 28
- Material event report (treasury share disposal)
InBody disclosed a plan to sell treasury shares worth US$151K, about 0.0% of its market value.
Treasury Shares · May 20 - Operating results (consolidated) (preliminary) (fair disclosure)
InBody filed provisional (unaudited) consolidated results for Q1 2026: revenue of US$47M (+23.1% year on year), operating profit of US$8.95M (+86% year on year) and net income of US$11.2M (+138.1% year on year).
Earnings · May 7 - [Amended] Cash/in-kind dividend decision
InBody updated its declared cash dividend of US$0.41 per share, equal to about 1.72% of the recent share price.
Dividend · Mar 11 - Treasury share disposal: results reportTreasury Shares · Mar 6
- Cash/in-kind dividend decision
InBody declared a cash dividend of US$0.42 per share.
Dividend · Feb 26 - Operating results (consolidated) (preliminary) (fair disclosure)
InBody filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$43.7M (+13.3% year on year), operating profit of US$6.67M (+26.9% year on year) and net income of US$4.45M (−24.5% year on year).
Earnings · Feb 26 - Material event report (treasury share disposal)
InBody disclosed a plan to sell treasury shares worth US$80.9K, about 0.0% of its market value.
Treasury Shares · Feb 26